Deltec Asset Management LLC has expanded its stake in Ocular Therapeutix by 2.9% during the second quarter. In total, the firm owns 2,794,892 shares after purchasing an additional 78,519 shares, reflecting the importance of the biopharmaceutical company in Deltec’s overall portfolio.